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Abstract
Anew and improved vaccine against tuberculosis (TB)would provide a powerful tool to conquer one of themost insidious infectious diseases of
mankind. Protection afforded by bacillus Calmette-Guerin (BCG) has been shown to be limited and inconsistent, especially in adults that are
known to transmit TB disease. In the last two decades, several new vaccines have been developed and tested with the aim to elicit robust and
long-lived T-cell responses againstMycobacterium tuberculosis antigens. Although much progress has been made in the TB vaccine ﬁeld, there is
an urgent need to address critical research questions about TB immunity with a special focus on designing vaccines aimed at preventing infection
and transmission of TB. Here, we discuss the rationale behind the current immunization strategies being implemented for TB vaccines and
provide some suggestions for hypothesis driven research to encourage the development of novel TB vaccines.
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The Critical Need for an Effective Vaccine
for Tuberculosis
Once considered a disease of the past, tuberculosis (TB) has
re-emerged in the last 30 years as a major threat in many parts
of the world. The latest WHO report estimates 1.3 million
deaths in 2012 and an incidence of 8.6 million TB disease cases
[1]. Globalization is changing the epidemiology of TB, with the
emergence of drug-resistant strains seen as a major concern
[2,3]. New tools are urgently needed to control TB at a global
level and the availability of an effective vaccine will contribute
to reduce TB incidence and mortality [4].
Bacillus Calmette–Guerin (BCG) remains the only vaccine
available for TB [5]. It is still routinely administered in
countries where TB is endemic to newborns immediately
after birth because of its efﬁcacy in preventing the most
severe forms of TB in early childhood [6]. There is
consensus that BCG is unable to provide signiﬁcant protec-
tion against pulmonary TB in adults [7,8], which is the only
form that promotes Mycobacterium tuberculosis transmission
[9]. In the last decade, a renaissance in TB research has
resulted in the development of many new experimental
vaccines, some of which were shown to induce in animal
models a protective immune response superior to that
induced by BCG (Table 1) [10–13]. More than ﬁfteen
of these new vaccines have entered or completed clinical
trials.
A T-cell-based Approach to TB Vaccine
Design
The fundamental rationale for the development of TB vaccines
designed to elicit T-cell-based immunity is based on the
assumption that eliciting a strong T helper type 1 immune
response speciﬁcally directed against M. tuberculosis antigens
provides a rapid mobilization of T cells at the site of primary
infection that can control bacterial replication and prevent
progression to active disease (Fig. 1) [10]. The central role of
T-cell immunity in controlling mycobacterial infection is well
established as illustrated by the enhanced susceptibility to TB
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infection and disease of subjects with impaired T-cell
responses, such as those with primary or acquired immun-
odeﬁciencies as observed in HIV-infected subjects or patients
undergoing anti-tumour necrosis factor therapy [34,35]. Many
studies in mice have clearly demonstrated the essential role of
T cells in controlling M. tuberculosis growth in vivo and the
pivotal role of interferon-c, a cytokine that is integral to the
cell-mediated immune response [36–38]. Additionally, it is well
established that T-cell responses are also involved with the
immunopathology and tissue damage associated with TB
disease [39,40].
An example of a T-cell-based TB vaccine strategy is the
development of the modiﬁed vaccinia Ankara (MVA) strain
expressing the mycobacterial antigen Ag85A. This vaccine
candidate, called MVA85A, boosts anti-tuberculous activity in
animals previously immunized with BCG that is associated with
induction of Ag85A-speciﬁc, interferon-c-secreting T cells [41–
43]. These animal models were speciﬁcally designed to test
immunization strategies that would be considered feasible in
human prime-boost studies. Subsequently, MVA85A was found
to be safe and immunogenic in children [44,45] and a
double-blind, randomized, placebo-controlled, phase 2b trial
TABLE 1. New tuberculosis vaccine candidates under development
Type of vaccine Name Description Ref.a
Live attenuated Mtb MTBVAC Unmarked double mutant missing the global regulator phoP and the phthiocerol dimycocerosates
(DIMs) -biosynthetic gene fadD26; enhanced protection in animal models
[14]
Mtb DsigE Mutant missing the gene for the alternative sigma factor SigE; differential modulation of innate
immune responses; enhanced protection in mice
[15]
Mtb DsecA2 Mutant missing secA2, encoding for a component of a virulence-associated secretion system,
results in a proapoptotic attenuated strain that warrants enhanced CD8 T-cell priming
[16]
Recombinant BCG rBCG30 rBCG overexpressing Ag85B; enhanced immunogenicity and protection in mice and guinea pigs [17]
BCG::RD1-2F9 rBCG complemented with the ESX-1 region from Mtb; enhanced protection in animals [18]
VPM 1002 rBCG DureC::hly, deleted in the urease gene and expressing listeriolysin to promote phagosome
lysis resulting in better antigen presentation, enhanced protection in mice
[19]
AERAS-422 rBCG expressing perfringolysin and several Mtb antigens, leads to phagosome lysis resulting in better
antigen presentation, enhanced protection in mice; phase I terminated due to side effects
[20]
rBCG PE_MPT64 rBCG overexpressing MPT64 on its surface resulting in enhanced protection in mice [21]
Recombinant NTM IKEPLUS Mycobacterium smegmatis Desx-3 complemented with Mtb esx-3; stimulation of protective bactericidal
immunity against Mtb in mice
[22]
Viral vectored MVA85A Vaccinia virus Ankara expressing Ag85A: enhanced protection in animal models, no efﬁcacy in
phase 2-b trial
[23]
AdAg85A Replication-deﬁcient adenovirus expressing Ag85A, enhanced protection in animal models [24]
AERAS-402 Replication-deﬁcient adenovirus expressing Ag85A, Ag85B and TB10.4, enhanced protection in
animal models
[25]
Protein subunit H1 Fusion protein Ag85B-Esat6, enhanced protection in animal models; safe and immunogenic in humans [26]
H56 Fusion protein Ag85B-ESAT-6-Rv2660c, enhanced protection in animal models, prevents tuberculosis
reactivation in monkeys
[27]
H4 Fusion protein AG85B-TB10.4; strong protection in animal models [28]
Mtb72F Fusion protein PepA-PPE18, long-term protection in non-human primates [29]
ID93 Fusion protein Rv2608-Rv3619-Rv3620-Rv1813; increased protection in BCG-vaccinated guinea pigs after boosting [30]
HBHA Mycobacterial heparin-binding haemagglutinin, good protection in mice [31]
Therapeutic vaccines Mycobacterium vaccae Killed M. vaccae; improves the efﬁcacy of chemotherapy [32]
RUTI Liposomes containing detoxiﬁed fragmented Mtb cells; reduces treatment time in animal models [33]
aOnly one relevant for each experimental vaccines has been selected.
Abbreviations: BCG, bacillus Calmette–Guerin; Mtb, Mycobacterium tuberculosis; NTM, nontuberculous mycobacteria.
FIG. 1. Schematic showing a model of a typical anti-mycobacterial immune response based on T cells that may be induced by bacillus Calmette–
Guerin and some of the vaccines currently under development. These vaccines elicit a T-cell immune response directed against Mycobacterium
tuberculosis (Mtb) antigens and rapid mobilization of these T cells and recruitment of other leucocytes at the site of bacterial replication warrants a
robust and more effective control of Mtb compared with non-immunized subjects. IFN-c, interferon-c; PMN, polymorphonuclear cells.
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was performed in South Africa, a country with a high burden of
TB, to measure the activity of MVA85A in previously
BCG-immunized infants [23]. Boosting with MVA85A was
well tolerated and an Ag85-speciﬁc CD4-positive T-cell
response, predominantly expressing interferon-c, tumour
necrosis factor-a and interleukin-2, was measured in ex vivo
assays in children boosted with MVA85A but not in the
placebo group, yet no efﬁcacy against TB or M. tuberculosis
infection was measured in the MVA85A immunized children
compared with the placebo group [23].
The lack of any measurable improved protective activity in
children for MVA85A, one of the most promising vaccines
against TB, compared with BCG, has been a wakeup call for
the TB vaccine community. Since many of the new TB vaccines
in clinical trials or in advanced preclinical testing are using a
similar immunological rationale, geared to eliciting a strong
T-cell response directed against M. tuberculosis antigens [46],
in-depth study of the immunological responses and efﬁcacy of
other vaccines designed to enhance T-cell-based immunity will
be critical in assessing the true utility of this strategy.
Genome comparisons of strains representative of the global
diversity of the M. tuberculosis complex have demonstrated
that known human T-cell epitopes in M. tuberculosis are more
conserved than essential genes [47]. These ﬁndings suggest
that the immune responses elicited by these T-cell epitopes,
while essential for the survival of the individual human host,
might also be beneﬁcial for the bacteria [47,48]. T-cell
responses may contribute to human-to-human transmission
of M. tuberculosis, perhaps by directly causing the lung tissue
destruction and cavitation that facilitates spread of the bacilli
[47,49]. The implications of these ﬁndings for the development
of new vaccines against TB are particularly relevant, because
this theory suggests that vaccines aimed at inducing strong
T-cell responses against immune-dominant M. tuberculosis
antigens may paradoxically increase transmission. The lack of
valid animal models of disease and transmission mimicking
human TB is a major hurdle to dissecting the differential role of
T-cell immune responses and identifying key components
associated with protection or disease. This is particularly true
considering that most, if not all, of the TB vaccines tested to
date are aimed at preventing disease rather than infection.
None of the vaccines evaluated so far has been able to
reproducibly induce sterilizing immunity and prevent M. tuber-
culosis infection in animals, which inevitably leads to chronic/
persistent infection or overt disease. The lack of an immuno-
logical correlate of protection makes it necessary to evaluate
several parameters that measure vaccine activity in animal
models. Protection is measured as a reduction in bacterial loads
in lung and spleen tissues and quantitative/qualitative lessening of
the lung tissue damage as assessed by histopathological analysis
in vaccinated compared with naive animals, together with
BCG-immunized groups used as the reference standard [50].
Overall, it is unclear whether and how any of the responses to
vaccines measured in animals translate into a conﬁdent assess-
ment of vaccine protection against TB infection or disease. It
also remains unclear whether improvements in the degree of
reductions in mycobacterial loads would predict enhanced
ability to prevent disease development or infection in humans.
The results of Tameris et al. [23] in part challenge the notion
that a vaccine capable of producing enhanced protection in
preclinical animal models will be more efﬁcacious in humans,
suggesting that the present parameters for selection of TB
vaccine candidates might be inadequate.
Targeting M. tuberculosis Transmission
A major limitation of BCG vaccine is its inability to provide any
measurable effect on limiting transmission of theM. tuberculosis
organism. This present the danger that new TB vaccine
approaches based on BCG or on BCG prime-boost strategies
may not interrupt transmission, thereby failing to provide the
public health beneﬁts that are classically associated with
vaccination [51]. The outcomes of transmission of M. tubercu-
losis are a function of the active pulmonary TB patient’s
infectiousness and of the newly infected host’s susceptibility
(Fig. 2a). Progression to disease, also depends upon bacterial
replication, tissue damage and cavitation in the lung tissue, which
is the result of a complex and dynamic host–pathogen interplay
and which potentially could be inﬂuenced by a vaccine-induced
immune response [52]. A vaccine capable of limiting extensive
tissue damage, preventing cavitation in the lung, or diverting
bacteria towards extrapulmonary sites where they can be
successfully scavenged may limit transmission [51]. Unfortu-
nately, the relevant information and comprehensive under-
standing of the immunological determinants associated with
tissue destruction and lung cavitation required to design a
vaccine speciﬁcally aimed at blocking transmission are lacking
[53]. The identiﬁcation of antigens expressed by M. tuberculosis
in the lung tissue during chronic infection [54], the character-
ization of their immunomodulatory role and their use in vaccines
could limit cavitation and bacterial release through the airways.
Candidate antigens for this approachmay exist and could include
the PE_PGRS proteins, which are unique to the MTB complex
and a few other pathogenic mycobacteria, have powerful
immunomodulatory properties and are over-represented in
granulomas of M. tuberculosis-infected guinea pigs [54–56].
The initial steps by which exposure to M. tuberculosis results
in the establishment of infection are not completely under-
stood and have mainly been inferred from studies measuring
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conversion of contacts to pulmonary TB patients assessed by
the tuberculin skin test. Estimates suggest that infection occurs
in only 20–50% of subjects who inhale the tubercle bacillus
[57]. The introduction of the more sensitive interferon-c
release assays (IGRAs) to detect and monitor M. tuberculosis
infection has provided a new view on the dynamic role of the
T-cell responses in the early steps of infection [58,59]. It has
been shown that IGRA conversions among household contacts
may, in a few subjects, eventually revert to negative and this
event is more likely to occur in individuals who are tuberculin
skin test negative and who show levels of interferon-c
responses in the Quantiferon assay slightly above the recom-
mended threshold [60]. This dynamic T-cell response has led
to the concept of ‘transient’ infection, deﬁned as an acute
resolving infection with the complete clearance of the bacilli,
an outcome inversely correlated with the dose of infection
[61]. These ﬁndings provide experimental evidence suggesting
that M. tuberculosis is relatively difﬁcult to transmit and that a
vaccination strategy that speciﬁcally targets the transmission
process, either by reducing bacterial spreading and/or enhanc-
ing antibacterial activities in the early steps of infection, may
have a signiﬁcant impact on the control of TB. To date, the lack
of reliable animal models has prevented the evaluation of
vaccine strategies aimed at blocking TB transmission.
What about Antibodies?
Most approved vaccines against respiratory pathogens are
believed to mediate protection by generating an antibody
response that neutralizes the infecting inoculum on mucosal
surfaces, so reducing the pathogen’s transmission [62]. The
role of antibodies in TB pathogenesis has been questioned for
more than a century and the common assumption is that
humoral responses play little or no role in protection against
TB or intracellular pathogens in general [63,64]. This concept
is supported by the observation, in animals and humans, that
antibody titres against mycobacterial antigens are highest
during TB disease and correlate with M. tuberculosis burden,
not with protection against infection [65]. The role of
antibody-mediated immunity against TB has been extensively
reviewed [64] and, based on an assessment of the experimen-
tal evidence, two potential mechanisms of protection have
been proposed by the authors. Antibodies could exert their
activity by interacting with host immune mediators or by
binding mycobacterial antigens with immunomodulatory prop-
erties and promoting their clearance, thereby modulating
anti-inﬂammatory or pro-inﬂammatory responses in infected
hosts, which may impact disease outcome [64,66]. In the
(a)
(b)
FIG. 2. Rationale for a vaccine strategy aimed at blocking transmission. (a) Vaccines may potentially prevent Mycobacterium tuberculosis (Mtb)
transmission in two different ways. (I) By inducing an immune response that limits tissue damage and cavitation in lung tissues while not necessarily
preventing infection or disease; (II) by inducing an immune response that prevents infection by enhancing antimicrobial responses occurring in the
early steps of infection. (b) Development and evaluation of anti-infective vaccines require proper experimental models that mimic Mtb transmission.
TB, tuberculosis.
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context of the damage-response framework [67], antibodies
may help to limit tissue damage and cavitation or may promote
M. tuberculosis dissemination and TB worsening [64]. More
extensive studies of the humoral response during M. tubercu-
losis infection may lead to new strategies to limit tissue
destruction in the lung tissue and reduce TB transmission.
Antibodies may also exert their protective activity by directly
binding bacterial surface components. Phagocytosis of opson-
ized M. tuberculosis has been shown to enhance intracellular
killing in macrophages [68,69], which may increase bacterial
clearance following infection. Antibodies directed against
HBHA, amycobacterial adhesin, were shown to reduce bacterial
dissemination from the site of primary infection in mice [70]. A
monoclonal antibody against arabinomannan increased survival
of M. tuberculosis-challenged mice [71] and antibodies directed
against the non-proteinaceous surface component lipoarabino-
mannan were shown to exert a protective activity [72].
Although studies such as these have suggested that antibodies
may have a role in a protective response against TB, the results of
passive immunization studies using puriﬁed antibodies have been
equivocal [64]. Nevertheless, more attention should be given to
the development of vaccines speciﬁcally aimed at inducing
humoral responses as well as investigating the role of B cells in
TB immunity.
Critical Research Questions
Since infection with M. tuberculosis occurs with inhalation of a
few bacilli, antibodies that attack the pathogen and/or enhance
antimicrobial defences during these early steps of infection
have the potential to elicit anti-infective immunity. To imple-
ment and test this hypothesis there are several questions and
areas of research that need to be addressed (Fig. 2b). These
include the following:
1. A better characterization of the M. tuberculosis surface
constituents, with emphasis on proteins involved in the early
steps of infection, is necessary to identify candidate antigens
for the development of anti-infective vaccines against TB.
For instance, it is well known that entrance of M. tuberculosis
into macrophages through the CR3 receptor enhances the
chance of mycobacterial survival in the intracellular niche
[73]. Identiﬁcation of the bacterial determinants involved in
this receptor-mediated entry may open new avenues to
develop antibody-based vaccine strategies. Analysis of
surface glycolipids and polysaccharides, which have been
neglected as vaccine antigens, is also needed.
2. Currently, in vitro and in vivo experiments aimed at testing
new vaccines are carried out with M. tuberculosis grown in
liquid culture, in media containing detergent to limit
bacterial clumping. These conditions alter the natural
organization of the mycobacterial surface. Ideally, experi-
ments used to test antibody-based strategies should use
bacteria with a well-preserved surface, resembling that of
bacilli released by a patient with active pulmonary TB.
Bacteria released by superinfected and dying macrophages
or obtained by homogenization of lung tissues from infected
animals may offer a better model to measure the ability of
antibodies to bind surface constituents.
3. The animal models currently used to assess vaccine efﬁcacy
rely on a low-dose aerogenic infection with M. tuberculosis
(c.100 CFU/animal). Protection is measured as a reduction
in Log CFU/organ of M. tuberculosis in vaccinated animals
compared with control animals. The protective activity of
anti-infective vaccines ideally should be measured in models
that better mimic human transmission, such as challenge
models using a very low dose of infection (<10 CFU/animal)
preferentially administered in multiple, consecutive doses. In
these models, protection should be measured as the
per cent of infected animals in the vaccinated animals versus
control animals rather than as reduction in CFUs. This
approach is similar to those routinely performed when
testing anti-infective vaccines against other bacterial patho-
gens [74,75]. In this experimental model, greater numbers of
animals need to be infected with M. tuberculosis and infection
could be identiﬁed by a simple IGRA-like assay.
4. The identiﬁcation of important M. tuberculosis antibody-pro-
ducing surface constituents involved in the interaction with
host components during the early steps of infection should
be better deﬁned in human populations. In this context, it
would be important to investigate whether uninfected close
contacts of TB patients, or subjects in whom a transient
infection has been demonstrated, have antibodies against
certain antigens of M. tuberculosis in the sera or mucosal
surfaces (bronchioalveolar lavage).
Although progress has beenmade in the TB vaccine ﬁeld over
the past decade and a ﬁrst generation of vaccines is being tested
in clinical trials, an urgent need to address critical research
questions about TB immunity still exists. One primary question
needs to be addressed: what responses to a vaccine need to be
induced to control the infection and transmission of TB?
Progress on the next generation of TB vaccines will probably
require creative but testable responses to this question.
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